The FDA has approved Flex Pharma's (FLKS) Investigational New Drug (IND) application related to FLX-787. The company intends to initiate a U.S. Phase 2 clinical trial in patients with amyotrophic lateral sclerosis (ALS) this summer. It also plans to submit a protocol for a mid-stage study in Charcot-Marie-Tooth (CMT), a group of inherited neuropathies.
The company describes FLX-787 as a transient receptor potential ion channel activator.
Previously: Flex Pharma shifts clinical activities to severe neurological diseases (Jan. 24)